Yiming Yao – CEO, Ronnsi, China
Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next…
Suzhou Ronnsi Pharma Co., Ltd. was founded in November 2012, with focus on complex drug research and development through integration of chemistry, biology, enzyme technology, analytical techniques, and bioinformatics. This platform technology has enabled us to develop several complex generic drugs such as enoxaparin, Copaxone and Abraxane. It also led us to discover and develop the novel drug candidate, dHG.
Collaborating with world-renowned experts and leading institutes in heparin chemistry and biology, we have developed the first non-porcine based enoxaparin – ovine enoxaparin.
Contact
Suite 507, Building C19, Suzhou bioBAY, 218 Xinghu Street, Suzhou Industrial Park, Jiangsu Province, China
Tel: +86 512 6295 6210
Serial entrepreneur and Ronnsi CEO Yiming Yao discusses the inspiration behind the company’s formation, its unique specialization in ovine heparin, and his strategy to take the firm to the next…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include InnoCare and Eli Lilly’s $3.35B licensing deal for five programs, BoomRay licensing a preclinical radioligand therapy to Novartis for $900M,…
The global AI-in-clinical-trials market is forecast to grow at a 22.6 percent CAGR through 2030, reaching roughly USD 6.5 billion, as sponsors push CROs to demonstrate concrete efficiency gains rather…
China has rapidly become the world’s leading country for clinical trial volume, alongside the stratospheric growth of its local biotech industry, which now accounts for almost a third of the…
Chinese biotechs are now outpacing multinationals at getting drugs into pivotal trials — but MNCs still win the race to final approval. In this piece from the September 2026 edition…
Excalipoint is betting that the next chapter of T-cell engagers will be written in solid tumours, where the modality is beginning to challenge the boundaries of cancer immunotherapy. Co-Founder, Chairman…
CirCode Biomed is emerging at the forefront of a small but fast-evolving field seeking to turn circular RNA into a new class of medicines. From its roots in pioneering academic…
Chinese pharmaceutical companies are increasingly seeking drug approval in the EU, US, and Australia, beyond the NMPA. Daphne Smyth of Veristat has witnessed this shift firsthand, advising sponsors on data…
Five conferences, anxiety spreading across five continents, one unmistakable pattern: the global pharmaceutical industry is transforming at a dizzying pace. From Philadelphia to Geneva, from Istanbul to Chicago and London,…
For two decades the case for running a clinical trial in Asia was essentially arithmetic: the same study, for less money. That argument has not gone away, but it is…
Our goal is to generate rigorous clinical data demonstrating that these therapies can deliver meaningful and lasting benefits for patients For decades, neurological diseases such as Parkinson’s disease, spinal cord…
China has built one of the world’s most advanced digital health ecosystems — large, fast-moving, and integrated across hospitals, internet platforms, insurers, pharmaceutical companies, and regulators. AI is now embedded…
As the global clinical development landscape becomes more fragmented and competitive, biotechs increasingly need partners that can help them navigate regulatory complexity, identify the right trial locations, and generate meaningful…
See our Cookie Privacy Policy Here
